AI
Commented by André Will-Laudien on October 10th, 2025 | 07:10 CEST
The AI tech high-flyers! Up to 3,500% dream returns with D-Wave Quantum, Power Metallic, Nvidia and AMD
Hard to believe, but unfortunately true! Without a single setback, share prices in the AI, high-tech, and strategic metals sectors have been rising unabated for months now. This has led to dream returns, some of which are in the triple digits. The curtain call for this party seems a long way off, while underinvested investors are sitting on billions in idle cash. There is no conclusive advice for such a situation. Fundamental analysts have been sounding the alarm for months, noting that the well-known Shiller P/E ratio, at over 42, has long since broken through the band of irrational exaggeration. But who cares? Here is a selection of stocks that face daily demand, forcing constant appreciation. Of course, as with any party, it only ends when the last guest turns off the lights.
Read
Commented by Armin Schulz on October 9th, 2025 | 07:40 CEST
AI paves the way to the next blockbuster: The current situation at Novo Nordisk, NetraMark Holdings and Evotec
The pharmaceutical industry is at a historic turning point. Artificial intelligence is breaking through the lengthy and costly development cycles that have characterized the sector for decades. This technological quantum leap is revolutionizing drug discovery and promises to transform healthcare from the ground up. The first companies to master this AI revolution will be the biggest winners in a billion-dollar market. We therefore take a look at three companies that are already using AI today: the Danish pharmaceutical giant Novo Nordisk, AI specialist NetraMark Holdings for clinical studies, and the German research service provider Evotec, and analyze their current situation.
Read
Commented by Carsten Mainitz on October 7th, 2025 | 07:45 CEST
Aspermont, Palantir, RENK – AI sets the pace. Where is the next run?
International stock markets are booming. The Dow Jones recently surpassed 47,000 points, seemingly unaffected by the US government shutdown. The topic of artificial intelligence (AI) continues to be the focus of investor interest, and recent company announcements are causing a stir. Japanese electronics giant Hitachi and ChatGPT provider OpenAI are partnering to build AI infrastructure and global data centers. Meanwhile, Fujitsu and leading AI chip manufacturer Nvidia are expanding their collaboration and plan to jointly develop a platform that uses AI in a targeted manner for specific industries, such as healthcare and robotics. In view of the AI boom, it is becoming increasingly compelling to explore second- and third-tier stocks that could benefit from the surge in innovation and investor interest.
Read
Commented by Stefan Feulner on October 7th, 2025 | 07:35 CEST
AMD, NetraMark, Adobe – AI latecomers with significant catch-up potential
The market is currently hotly debating when the AI bubble will finally burst. Investors are becoming increasingly nervous, as the valuations of many companies, such as Palantir and Nvidia, are at levels seen just before the dot-com bubble in the early 2000s. However, not all companies related to artificial intelligence are overvalued. Especially in niche segments, there are still hidden gems to be found that have the potential to multiply in value.
Read
Commented by André Will-Laudien on October 7th, 2025 | 07:00 CEST
Total boom! Not 10% returns per year, but per day! The portfolio rockets: Almonty, Plug Power, Nel ASA and AMD
The financial markets are in a bullish mood. But not all stocks are performing like Almonty Industries, where the surge is driven purely by fundamental revaluation. After the gold rush in 2020/2021, hydrogen stocks underwent a prolonged 95% correction. For US industry leader Plug Power, this meant a sell-off from over USD 12 to a low of USD 0.75. In May, the correction came to an end, and the stock skyrocketed to over USD 4.75 yesterday – a fivefold increase in just four months. Nel ASA has followed a similar path, with a 15% turnaround from the bottom yesterday. These extreme movements are evidence of very high market liquidity. AMD surprised with a deal with OpenAI - fueling a 25% jump. The helium balloon keeps rising. Here is an overview of the action.
Read
Commented by André Will-Laudien on October 2nd, 2025 | 07:25 CEST
AI fuels cancer research: Bayer, Vidac Pharma, and Pfizer are the next 150% winners
The stock market remains strong! In addition to the tech and defense boom, the biotech sector has also been catching up in recent days, with the latest news in cancer research bringing the industry back into the spotlight. The key factor here is artificial intelligence, which is revolutionizing cancer research through personalized therapy approaches based on the evaluation of extensive clinical and genetic data. AI models make it possible to predict individual cancer progression better and tailor therapies to individual patients. By analyzing multimodal data, AI systems can more accurately assess the risk of metastasis and thus develop targeted treatment strategies. AI has also improved tumor diagnostics by accurately detecting numerous types of cancer, therefore ensuring a more precise diagnosis.
Read
Commented by Carsten Mainitz on October 2nd, 2025 | 07:10 CEST
NetraMark Holdings, Evotec, Sartorius – Billion-dollar deals in sight!
Artificial intelligence and machine learning have become key drivers across nearly every industry. When pharmaceutical companies successfully develop a drug to market readiness, profits can surge. However, only a few active ingredients that enter clinical trials ultimately receive approval. It is therefore a long, risky, and costly process. The use of AI can help to minimize these risks significantly. Here, we take a look at the potential of AI-based strategies among established players Evotec and Sartorius, with a particular focus on the innovative approach of Canadian company NetraMark Holdings.
Read
Commented by André Will-Laudien on September 30th, 2025 | 07:35 CEST
High-tech super boom! 1,000% no problem—here is more from D-Wave, NetraMark and Palantir!
Artificial intelligence (AI) is currently revolutionizing drug development by analyzing enormous amounts of data in a very short time and making clinical trials much more targeted. Modern AI systems make it possible to select drug candidates with precision and predict the potential success of a therapy with a high degree of accuracy. Companies like NetraMark are already using these technologies profitably. Players such as D-Wave and Palantir are also among the pioneers of the new AI-driven economy and have seen their share prices rise by over 1,000%. Expectations for further growth are virtually limitless. The advent of quantum computer technology also marks the beginning of a new chapter in ultra-fast data processing. For forward-looking investors, this opens up attractive entry opportunities in dynamically expanding future markets. Those who bet on the right players early on can benefit from this change to an above-average extent.
Read
Commented by Stefan Feulner on September 29th, 2025 | 07:05 CEST
SAP, Aspermont, AppLovin – AI models with powerful upward momentum
The combination of big data and artificial intelligence is considered one of the biggest growth drivers of the coming decade. Companies that manage to efficiently collect and evaluate vast amounts of data and make it usable in real time not only gain competitive advantages but also redefine entire industries. Whether in healthcare, finance, commodities, or industry, those who use data intelligently can optimize processes, reduce costs, and develop entirely new business models. Investors should not underestimate this dynamic.
Read
Commented by Nico Popp on September 26th, 2025 | 07:30 CEST
AI is conquering increasingly more areas: SAP and Amazon are targeting small and mid-sized businesses, while NetraMark is winning over the biotech industry
Will AI become our new god? This question is currently being explored in depth by the German philosopher Markus Gabriel in a well-known German podcast. And although the question may cause unease for many, Gabriel's conclusions are ultimately anything but pessimistic. SAP and Amazon are also looking to the future with optimism: Together with OpenAI, they are now building an AI infrastructure in Germany. The goal: to enable public authorities and companies to use the latest AI tools in a legally compliant manner, without European data leaving the continent. The initiative demonstrates that AI will conquer many more areas in the coming years. One of these areas is medical research. The innovative company NetraMark is using its AI solution to deliver faster results and lower costs for future-focused projects, such as the fight against cancer.
Read